Physician profile
Michael A Campos
NPI 1366489320
$70,045.52
in general payments reported to CMS, 2019-2025
14 companies · $8,508 in 2025
The $8,508 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $13K · 2021: $7,353 · 2022: $15K · 2023: $6,594 · 2024: $158 · 2025: $8,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $3,536 · Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,123.50 |
| Travel and Lodging | $3,536.02 |
| Food and Beverage | $1,599.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $33,716.09 | 2019-2022 | |
| Grifols USA, LLC | $13,177.17 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,981.00 | 2020-2025 | Glassia |
| Grifols Shared Services North America, INC. | $7,185.46 | 2022-2025 | Prolastin-C Liquid |
| Chiesi USA, INC. | $4,465.42 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,102.52 | 2019 | |
| Genzyme Corporation | $405.50 | 2025 | |
| Gilead Sciences, INC. | $12.36 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.